torl-1-23
torl biotherapeutics
['ovarian', 'torl,1,23']
 s gottfried konecny, md, presents #asco23 from 8-11 at a poster session on ovarian cancer his research titled initial results of dose finding in a first-in-human phase 1 study of claudin 6 (cldn6) targeted antibody drug conjugate (adc) torl-1-23. hall a. 
We are accelerating discoveries to prevent and cure cancer.